MX2010001975A - Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso. - Google Patents
Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso.Info
- Publication number
- MX2010001975A MX2010001975A MX2010001975A MX2010001975A MX2010001975A MX 2010001975 A MX2010001975 A MX 2010001975A MX 2010001975 A MX2010001975 A MX 2010001975A MX 2010001975 A MX2010001975 A MX 2010001975A MX 2010001975 A MX2010001975 A MX 2010001975A
- Authority
- MX
- Mexico
- Prior art keywords
- derivatives
- cxcr5
- humanized anti
- cxcr5 antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
La presente invención se refiere a anticuerpos humanizados que se unen específicamente a CXCR5 y, por ejemplo, pueden inhibir la función de CXCR5. La invención también incluye usos de los anticuerpos para tratar o prevenir enfermedades o trastornos relacionados con CXCR5.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96879207P | 2007-08-29 | 2007-08-29 | |
PCT/US2008/074381 WO2009032661A1 (en) | 2007-08-29 | 2008-08-27 | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010001975A true MX2010001975A (es) | 2010-03-10 |
Family
ID=40429297
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013005976A MX338395B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso. |
MX2010001975A MX2010001975A (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso. |
MX2013014465A MX338397B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
MX2013014467A MX346172B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
MX2013014466A MX338474B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013005976A MX338395B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso. |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013014465A MX338397B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
MX2013014467A MX346172B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
MX2013014466A MX338474B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
Country Status (44)
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120263733A1 (en) * | 2002-11-15 | 2012-10-18 | Morehouse School Of Medicine | Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation |
USRE47123E1 (en) | 2006-07-18 | 2018-11-13 | Sanofi | EPHA2 receptor antagonist antibodies |
UY31309A1 (es) | 2007-08-29 | 2009-03-31 | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso | |
MX2011001696A (es) * | 2008-08-14 | 2011-03-25 | Merck Sharp & Dohme | Metodos para purificar anticuerpos usando cromatografia de afinidad con proteina a. |
FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
TW201116297A (en) | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
MX343228B (es) | 2009-11-30 | 2016-10-26 | Biotest Ag | Anticuerpos anti-il-10humanizados para el tratamiento de lupus sistémico eritematoso. |
EP2397495A1 (en) | 2010-06-21 | 2011-12-21 | Sanofi | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
EP2336188A1 (en) | 2009-12-18 | 2011-06-22 | Sanofi-Aventis | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
MX347613B (es) | 2009-12-18 | 2017-05-04 | Sanofi Sa | Nuevos anticuerpos antagonistas y sus fragmentos fab contra gpvi y sus usos. |
EP2402371A1 (en) | 2010-07-01 | 2012-01-04 | Sanofi | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
FR2958936A1 (fr) | 2010-04-14 | 2011-10-21 | Sanofi Aventis | Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
TWI560199B (en) | 2010-08-31 | 2016-12-01 | Sanofi Sa | Peptide or peptide complex binding to α2 integrin and methods and uses involving the same |
UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
JP2014505239A (ja) * | 2010-12-14 | 2014-02-27 | モアハウス スクール オブ メディスン | 癌の治療または検出のための抗cxcl13および抗cxcr5抗体の使用 |
AR085302A1 (es) | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
RU2663141C2 (ru) | 2012-01-20 | 2018-08-01 | Джензим Корпорейшн | Анти-cxcr3 антитела |
ES2702246T3 (es) * | 2012-03-26 | 2019-02-28 | Sanofi Sa | Formulaciones de agente de unión IgG4 estables |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
BR122019026701B1 (pt) * | 2012-03-26 | 2023-01-24 | Sanofi | Formulações de agentes de ligação à base de igg4 estáveis, kit, e dispositivo ou recipiente pré-cheios |
EP2831113B1 (en) | 2012-03-28 | 2018-03-14 | Sanofi | Antibodies to bradykinin b1 receptor ligands |
EP2866830A4 (en) * | 2012-06-27 | 2015-12-09 | Jyant Technologies | ANTI-CXCL9, ANTI-CXCL10, ANTI-CXCL11, ANTI-CXCL13, ANTI-CXCR3 AND ANTI-CXCR5 AGENTS FOR THE INHIBITION OF INFLAMMATION |
WO2014003744A1 (en) * | 2012-06-27 | 2014-01-03 | Morehouse School Of Medicine | Anti-cxcl9, anti-cxcl 10, anti-cxcl 11, anti-cxcl 13, anti-cxcr3 and anti-cxcr5 agents for inflammatory disorder |
MY171100A (en) | 2012-11-20 | 2019-09-25 | Sanofi Sa | Anti-ceacam5 antibodies and uses thereof |
EP2925779A1 (en) | 2012-11-30 | 2015-10-07 | Institut Pasteur | Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock |
US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
EA201591219A1 (ru) | 2012-12-27 | 2015-12-30 | Санофи | Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение |
TWI612059B (zh) * | 2013-03-15 | 2018-01-21 | 美國禮來大藥廠 | 泛-ELR<sup>+</sup>CXC趨化因子抗體 |
JP6522585B2 (ja) * | 2013-05-02 | 2019-05-29 | アレス トレーディング ソシエテ アノニム | Cxcr5に対するモノクローナル抗体 |
KR20160022370A (ko) * | 2013-06-24 | 2016-02-29 | 넥스이뮨 | 면역요법을 위한 조성물 및 방법 |
TW201722994A (zh) | 2013-08-13 | 2017-07-01 | 賽諾菲公司 | 胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途 |
KR20160035077A (ko) | 2013-08-13 | 2016-03-30 | 사노피 | 플라스미노겐 활성인자 저해제-1(pai-1)에 대한 항체 및 그의 용도 |
WO2015143414A2 (en) * | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
AU2015305850A1 (en) | 2014-08-22 | 2017-04-06 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind CXCR5 |
SG11201705064XA (en) * | 2014-12-24 | 2017-07-28 | Neximmune Inc | Nanoparticle compositions and methods for immunotherapy |
TW202130662A (zh) | 2015-01-23 | 2021-08-16 | 法商賽諾菲公司 | 特異性結合cd3及/或cd123之抗—cd3抗體,抗—cd123抗體及雙特異性抗體 |
EP3313523A2 (en) | 2015-06-23 | 2018-05-02 | Bayer Pharma Aktiengesellschaft | Targeted conjugates of ksp inhibitors |
ES2875757T3 (es) | 2015-11-03 | 2021-11-11 | Merck Patent Gmbh | Anticuerpos biespecíficos para potenciar la selectividad e inhibición tumorales y sus usos. |
CN110452295B (zh) * | 2015-11-10 | 2022-10-11 | 孙嘉琳 | 抗肿瘤蛋白内皮抑素的衍生物 |
SG10202008909VA (en) | 2016-03-24 | 2020-10-29 | Bayer Pharma AG | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
JP7028855B2 (ja) * | 2016-07-05 | 2022-03-02 | サノフイ | 抗体製剤 |
TWI760345B (zh) | 2016-07-05 | 2022-04-11 | 法商賽諾菲公司 | 抗體調配物 |
TWI790206B (zh) | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白 |
EP3533465A4 (en) * | 2016-09-26 | 2020-07-01 | MPO, Inc. | EGG, FERTILIZED EGG OR MEANS TO IMPROVE EMBRYOQUALITY |
US11433140B2 (en) | 2016-12-21 | 2022-09-06 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (ADCs) having KSP inhibitors |
US20190351066A1 (en) | 2016-12-21 | 2019-11-21 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
JP7066714B2 (ja) * | 2016-12-21 | 2022-05-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 酵素的に切断可能な基を有する抗体薬物コンジュゲート(adc) |
US20180214542A1 (en) | 2016-12-22 | 2018-08-02 | Sanofi | Humanized cxcr3 antibodies with depleting activity and methods of use thereof |
WO2018119288A1 (en) | 2016-12-22 | 2018-06-28 | Sanofi | Anti-human cxcr3 antibodies for treatment of vitiligo |
EP3354278A1 (en) | 2017-01-31 | 2018-08-01 | Sanofi | Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide |
TWI808963B (zh) | 2017-03-22 | 2023-07-21 | 法商賽諾菲公司 | 使用人類化抗cxcr5抗體治療狼瘡 |
JP2020514386A (ja) * | 2017-03-22 | 2020-05-21 | サノフイSanofi | ヒト化抗cxcr5抗体を使用するループスの処置 |
JP2020521752A (ja) * | 2017-05-24 | 2020-07-27 | ディベロップメント センター フォー バイオテクノロジーDevelopment Center For Biotechnology | グロボhに対するヒト化抗体および癌治療におけるその使用 |
CN110831978A (zh) | 2017-06-30 | 2020-02-21 | 酵活有限公司 | 稳定的嵌合fab |
AU2018375331A1 (en) * | 2017-12-01 | 2020-05-14 | Pfizer Inc. | Anti-CXCR5 antibodies and compositions and uses thereof |
US20200360531A1 (en) | 2018-01-31 | 2020-11-19 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
WO2019159193A1 (en) * | 2018-02-13 | 2019-08-22 | Indian Institute Of Technology Bombay | Novel humanized anti-cd19 chimeric antigen receptor, its nucelic acid sequence and its preparation |
SG11202008620VA (en) * | 2018-03-26 | 2020-10-29 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
EA202190059A1 (ru) * | 2018-06-18 | 2021-04-21 | Байер Акциенгезельшафт | Конъюгаты связующее-активное средство, направленные против cxcr5, имеющие ферментативно расщепляемые линкеры и улучшенный профиль активности |
EP3753954A1 (en) | 2019-06-21 | 2020-12-23 | Université de Franche-Comté | Anti-cd123 antibodies, anti-cd123 chimeric antigen receptors and anti-cd123 chimeric antigen receptors t cells |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
EP4090365A1 (en) | 2020-01-15 | 2022-11-23 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
AU2021225962A1 (en) | 2020-02-28 | 2022-10-20 | Genzyme Corporation | Modified binding polypeptides for optimized drug conjugation |
WO2023010483A1 (en) * | 2021-08-05 | 2023-02-09 | Hifibio (Hk) Limited | Anti-human cxcr5 antibody and uses thereof |
CA3180872A1 (en) | 2020-04-24 | 2021-10-28 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates and cetuximab |
EP4138925A1 (en) | 2020-04-24 | 2023-03-01 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil |
KR20230005203A (ko) | 2020-04-24 | 2023-01-09 | 사노피 | 항-ceacam5 항체 접합체 및 folfox를 함유하는 항종양 조합 |
KR20230005257A (ko) | 2020-04-24 | 2023-01-09 | 사노피 | 항-ceacam5 항체 접합체 및 folfiri를 함유하는 항종양 병용물 |
CN116113439A (zh) | 2020-09-04 | 2023-05-12 | 默克专利股份公司 | 抗ceacam5抗体和缀合物及其用途 |
CN112521499B (zh) * | 2020-12-24 | 2022-10-25 | 四川大学 | 抗cxcl13抗体及其用途 |
US20240101673A1 (en) | 2021-02-03 | 2024-03-28 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
CA3211179A1 (en) * | 2021-03-09 | 2022-09-15 | Liang SCHWEIZER | Anti-human cxcr5 antibody and uses thereof |
WO2022241034A1 (en) * | 2021-05-12 | 2022-11-17 | BioLegend, Inc. | Anti-ccr8 antibodies, antigen-binding fragments thereof, and agents and compositions and methods for making and using the same |
CN113278072B (zh) * | 2021-05-25 | 2023-06-20 | 河南凯普瑞生物技术有限公司 | 一种抗体的制备方法 |
CN116547300A (zh) * | 2021-09-30 | 2023-08-04 | 贝达药业股份有限公司 | 双特异性抗体及其应用 |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
AU2022382383A1 (en) | 2021-11-05 | 2024-06-20 | Eli Lilly And Company | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies |
TW202346354A (zh) | 2022-03-09 | 2023-12-01 | 德商馬克專利公司 | 抗ceacam5抗體及其結合物及用途 |
WO2023172968A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof |
WO2023212587A1 (en) | 2022-04-28 | 2023-11-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant polypeptides comprising single-domain antibodies targeting herv-k subtype hml-2 |
WO2024011077A2 (en) | 2022-07-04 | 2024-01-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Monoclonal antibodies directed to phosphorylated psd95 and uses thereof |
CN117004700A (zh) * | 2023-10-07 | 2023-11-07 | 北京爱博生生物技术有限公司 | 单克隆抗体可变区基因高通量测序的方法及其所用组合物与试剂盒 |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4307016A (en) * | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4275149A (en) * | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) * | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
US4256746A (en) * | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) * | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) * | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS6023084B2 (ja) * | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
JPS5645483A (en) * | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) * | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) * | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
US4444887A (en) * | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
WO1982001188A1 (en) * | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) * | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) * | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) * | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) * | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4640835A (en) * | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4716111A (en) * | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4560655A (en) * | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) * | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4767704A (en) * | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) * | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4737456A (en) * | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
DE3675588D1 (de) * | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8601597D0 (en) * | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4791192A (en) * | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
JPH02503867A (ja) | 1988-04-15 | 1990-11-15 | プロテイン デザイン ラブズ インコーポレーテッド | Il‐2レセプター特異的キメラ抗体 |
JP3105898B2 (ja) | 1988-04-16 | 2000-11-06 | セルテック リミテッド | 組換えdnaタンパクの製造方法 |
WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
US5534617A (en) * | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
DE68913658T3 (de) * | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
IL94611A (en) * | 1989-06-05 | 1994-12-29 | Organogenesis Inc | Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use |
US5413923A (en) * | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
US5436146A (en) * | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
EP0463151B1 (en) * | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
EP0521985B1 (en) | 1990-03-20 | 1997-09-24 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DE69127627T2 (de) * | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
US5814318A (en) * | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992006180A1 (en) | 1990-10-01 | 1992-04-16 | University Of Connecticut | Targeting viruses and cells for selective internalization by cells |
US5122469A (en) * | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
AU660297B2 (en) | 1990-11-09 | 1995-06-22 | Stephen D. Gillies | Cytokine immunoconjugates |
DE69231736T2 (de) | 1991-05-14 | 2001-10-25 | The Immune Response Corp., Carlsbad | Gerichtete abgabe von genen, die immunogene proteine kodieren |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
ES2149774T3 (es) | 1991-06-05 | 2000-11-16 | Univ Connecticut | Aportacion dirigida de genes que codifican proteinas secretoras. |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ATE463573T1 (de) * | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
US5869619A (en) * | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
CA2076465C (en) * | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
EP0633943A4 (en) | 1992-04-03 | 1997-05-02 | Alexander T Young | GENTHERAPY USING TARGETED VIRAL VECTORS. |
AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
CA2141602A1 (en) * | 1992-08-26 | 1994-03-03 | Philip Leder | Use of the cytokine ip-10 as an anti-tumor agent |
US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
PT671923E (pt) | 1992-10-09 | 2001-10-30 | Advanced Tissue Sciences Inc | Celulas de reserva do figado |
WO1994012649A2 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Gene therapy for cystic fibrosis |
WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
US6165463A (en) * | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP1983057A3 (en) * | 1995-09-08 | 2009-01-07 | Genzyme Corporation | Improved AAV vectors for gene therapy |
AU5711196A (en) | 1996-03-14 | 1997-10-01 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
EP0904278A4 (en) | 1996-03-22 | 1999-09-15 | Human Genome Sciences Inc | MOLECULE II INDUCER OF APOPTOSIS |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP0970126B1 (en) | 1997-04-14 | 2001-04-18 | Micromet AG | Novel method for the production of antihuman antigen receptors and uses thereof |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6642051B1 (en) * | 1997-10-21 | 2003-11-04 | Targeted Genetics Corporation | Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors |
KR20010031713A (ko) | 1997-11-03 | 2001-04-16 | 벤슨 로버트 에이치. | 맥관형성 및 종양 성장 억제제인 맥관 내피 세포 성장억제제 |
PT1157041E (pt) * | 1999-03-01 | 2005-10-31 | Genentech Inc | Anticorpos para terapia e diagnostico de cancro |
EP1276756A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
RU2252786C2 (ru) * | 2000-09-08 | 2005-05-27 | Микромет Аг | Конструкции антител и хемокинов и их применение при иммунологических нарушениях |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
US20030220341A1 (en) * | 2001-12-21 | 2003-11-27 | Gary Bridger | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
AU2003239248A1 (en) * | 2002-06-07 | 2003-12-22 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And | Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins |
AU2003251471A1 (en) * | 2002-08-06 | 2004-02-25 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5) |
TW200530269A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
WO2006042333A2 (en) | 2004-10-12 | 2006-04-20 | Xencor, Inc. | Prediction and assessment of immunogenicity |
GB0607774D0 (en) * | 2006-04-20 | 2006-05-31 | Renovo Group Plc | Medicaments |
TW200813086A (en) | 2006-05-11 | 2008-03-16 | Hoffmann La Roche | Immunereconstituted mouse |
UY31309A1 (es) | 2007-08-29 | 2009-03-31 | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso |
-
2008
- 2008-08-27 UY UY31309A patent/UY31309A1/es not_active Application Discontinuation
- 2008-08-27 RU RU2015147300A patent/RU2015147300A/ru not_active Application Discontinuation
- 2008-08-27 HU HUE08798744A patent/HUE037489T2/hu unknown
- 2008-08-27 TR TR2018/07983T patent/TR201807983T4/tr unknown
- 2008-08-27 CN CN201410307133.3A patent/CN104017078B/zh active Active
- 2008-08-27 NO NO08798744A patent/NO2195023T3/no unknown
- 2008-08-27 PL PL08798744T patent/PL2195023T3/pl unknown
- 2008-08-27 KR KR1020107006630A patent/KR101599704B1/ko active IP Right Grant
- 2008-08-27 BR BRPI0815983A patent/BRPI0815983A2/pt not_active Application Discontinuation
- 2008-08-27 MY MYPI2010000837A patent/MY159201A/en unknown
- 2008-08-27 EP EP18154804.1A patent/EP3354662B1/en active Active
- 2008-08-27 SG SG10201407388XA patent/SG10201407388XA/en unknown
- 2008-08-27 LT LTEP08798744.2T patent/LT2195023T/lt unknown
- 2008-08-27 PA PA20088794201A patent/PA8794201A1/es unknown
- 2008-08-27 AU AU2008296538A patent/AU2008296538B2/en active Active
- 2008-08-27 MX MX2013005976A patent/MX338395B/es unknown
- 2008-08-27 UA UAA201312423A patent/UA117446C2/uk unknown
- 2008-08-27 WO PCT/US2008/074381 patent/WO2009032661A1/en active Application Filing
- 2008-08-27 DK DK08798744.2T patent/DK2195023T3/en active
- 2008-08-27 ES ES08798744.2T patent/ES2672769T3/es active Active
- 2008-08-27 KR KR1020157017528A patent/KR101701140B1/ko active IP Right Grant
- 2008-08-27 PT PT87987442T patent/PT2195023T/pt unknown
- 2008-08-27 SI SI200831964T patent/SI2195023T1/en unknown
- 2008-08-27 UA UAA201003491A patent/UA104715C2/uk unknown
- 2008-08-27 RU RU2010111751/10A patent/RU2571515C2/ru not_active IP Right Cessation
- 2008-08-27 US US12/675,799 patent/US8647622B2/en active Active
- 2008-08-27 JP JP2010523100A patent/JP5743543B2/ja active Active
- 2008-08-27 EP EP08798744.2A patent/EP2195023B1/en active Active
- 2008-08-27 MX MX2010001975A patent/MX2010001975A/es active IP Right Grant
- 2008-08-27 EP EP20191628.5A patent/EP3792284A1/en active Pending
- 2008-08-27 CA CA2698203A patent/CA2698203C/en active Active
- 2008-08-27 MX MX2013014465A patent/MX338397B/es unknown
- 2008-08-27 MX MX2013014467A patent/MX346172B/es unknown
- 2008-08-27 CN CN202010815880.3A patent/CN111909273B/zh active Active
- 2008-08-27 PE PE2008001444A patent/PE20090993A1/es not_active Application Discontinuation
- 2008-08-27 KR KR1020147023916A patent/KR20140117638A/ko not_active Application Discontinuation
- 2008-08-27 CN CN200880113572.3A patent/CN101842115B/zh active Active
- 2008-08-27 KR KR1020147026311A patent/KR101667944B1/ko active IP Right Grant
- 2008-08-27 NZ NZ583605A patent/NZ583605A/xx not_active IP Right Cessation
- 2008-08-27 RS RS20180659A patent/RS57273B1/sr unknown
- 2008-08-27 CN CN201410307453.9A patent/CN104017079B/zh active Active
- 2008-08-27 MX MX2013014466A patent/MX338474B/es unknown
- 2008-08-29 TW TW103111438A patent/TWI574976B/zh not_active IP Right Cessation
- 2008-08-29 CL CL2008002565A patent/CL2008002565A1/es unknown
- 2008-08-29 TW TW097133372A patent/TWI439468B/zh not_active IP Right Cessation
- 2008-08-29 TW TW105114943A patent/TWI608017B/zh not_active IP Right Cessation
- 2008-08-29 AR ARP080103776A patent/AR068354A1/es not_active Application Discontinuation
- 2008-08-29 TW TW106127131A patent/TW201741341A/zh unknown
-
2010
- 2010-02-19 NI NI201000028A patent/NI201000028A/es unknown
- 2010-02-19 NI NI2010000281A patent/NI201000281A/es unknown
- 2010-02-23 CR CR11293A patent/CR11293A/es unknown
- 2010-02-23 EC EC2010009985A patent/ECSP109985A/es unknown
- 2010-02-23 TN TNP2010000092A patent/TN2010000092A1/fr unknown
- 2010-02-24 SV SV2010003494A patent/SV2010003494A/es unknown
- 2010-02-25 IL IL204173A patent/IL204173A/en active IP Right Grant
- 2010-02-26 DO DO2010000069A patent/DOP2010000069A/es unknown
- 2010-03-02 ZA ZA2010/01514A patent/ZA201001514B/en unknown
- 2010-03-08 MA MA32673A patent/MA31821B1/fr unknown
- 2010-04-05 CO CO10037770A patent/CO6270238A2/es active IP Right Grant
-
2013
- 2013-03-11 US US13/794,253 patent/US20130243793A1/en not_active Abandoned
- 2013-03-11 US US13/794,281 patent/US9175087B2/en active Active
- 2013-03-11 US US13/794,244 patent/US9243067B2/en active Active
- 2013-03-11 US US13/794,224 patent/US9228019B2/en active Active
- 2013-03-11 US US13/794,264 patent/US8980262B2/en active Active
-
2014
- 2014-12-26 JP JP2014263780A patent/JP6129152B2/ja active Active
-
2015
- 2015-02-05 CR CR20150054A patent/CR20150054A/es unknown
- 2015-02-05 PH PH12015500248A patent/PH12015500248A1/en unknown
- 2015-04-28 IL IL238505A patent/IL238505A/en active IP Right Grant
-
2016
- 2016-08-22 US US15/243,046 patent/US9815902B2/en active Active
-
2017
- 2017-03-06 JP JP2017041210A patent/JP2017123866A/ja active Pending
-
2018
- 2018-01-03 US US15/725,253 patent/US20180100019A1/en not_active Abandoned
- 2018-06-05 HR HRP20180873TT patent/HRP20180873T1/hr unknown
- 2018-06-06 CY CY181100591T patent/CY1120665T1/el unknown
- 2018-07-20 AR ARP180102046 patent/AR112564A2/es unknown
-
2021
- 2021-08-20 US US17/407,651 patent/US20220073629A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
AU2016219704A1 (en) | Anti-Notch1 antibodies | |
MX2009008104A (es) | Hepcidina, antagonistas de hepcidina y metodos de uso. | |
MY177564A (en) | Anti-nr10 antibody and use thereof | |
MY155621A (en) | Axl antibodies | |
TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
MX2009013082A (es) | Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento. | |
MX2010005888A (es) | Anticuerpos bivalentes biespecificos. | |
MX2010005682A (es) | Anticuerpos bivalentes, biespecificos. | |
UA100874C2 (en) | Bivalent bispecific antibodies | |
MX2010006396A (es) | Anticuerpos bivalentes, biespecificos. | |
MY165273A (en) | Anti-cd48 antibodies and uses thereof | |
MX2009001110A (es) | Anticuerpos monoclonales anti-il-6 y usos de los mismos. | |
UA113397C2 (xx) | Попередження несприятливих ефектів, спричинених специфічними доменами зв'язування cd3 | |
MX2009006471A (es) | Anticuerpo anti especifico de linfopoyetina estromal timica de diseño. | |
WO2010032059A3 (en) | Antibodies directed to cd105 and uses thereof | |
MX2010004219A (es) | Agentes de enlace de cd19 y usos de los mismos. | |
MX2009006891A (es) | Anticuerpos cd44. | |
MY151191A (en) | Novel antibodies | |
WO2012149478A3 (en) | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases | |
EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 | |
WO2008097439A3 (en) | Anti-autoimmune antibodies for treatment of pemphigus | |
MY149492A (en) | Immunoglobulins directed against nogo | |
WO2008150530A3 (en) | Cripto binding molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
FG | Grant or registration |